MayBio Biomedical key facts
as of Oct 2026- Developer of surgical implant products containing human extracellular matrix and collagen designed for medical beauty.
- MayBio Biomedical is valued at approximately $11.4M as of Oct 2026 (last reported valuation).
- It has raised $2.9M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Hunan Chasing Fund, Alwin Capital, Century Golden Resources Group, Beijing New Aerotropolis Fund Management, Kefu Medical — 8 tracked in total.
- Status: Privately Held (backing).
MayBio Biomedical's last reported valuation, Aug 2020. Nothing priced has surfaced since.
- ·Watch MayBio Biomedical: the Monday email on marks, rounds and moves
MayBio Biomedical funding rounds
No funding rounds for MayBio Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
MayBio Biomedical valuation
MayBio Biomedical's last reported valuation was $11.4 million in Aug 2020. No priced round, secondary trade or fund mark has surfaced since.
MayBio Biomedical investors
8 investors are on record for MayBio Biomedical, including Hunan Chasing Fund, Alwin Capital, Century Golden Resources Group and Beijing New Aerotropolis Fund Management.
About MayBio Biomedical
Developer of surgical implant products containing human extracellular matrix and collagen designed for medical beauty. The company is committed to providing a series of overall medical solutions including cells, biomaterials, human growth factors and human collagen, enabling medical professionals to have better medical products to use.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Website
- maybio.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.